Clinical outcome of trabectedin in Japanese patients with soft tissue sarcoma; JMOG multicenter study

Clinical outcome of trabectedin in Japanese patients with soft tissue sarcoma; JMOG multicenter study - Clinical outcome of trabectedin in Japanese patients with soft tissue sarcoma; JMOG multicenter study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034206

Enrollment

200

Registered

2018-09-21

Start date

2017-09-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant soft tissue tumor

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The aim to use trabectedin is for local recurrent or metastatic tumor 2. The existence of tumors which can be evaluated by radiological examination when treatment using trabectedin is started.

Exclusion criteria

Exclusion criteria: Patients who are not treated in the registered institutions of Japanese Musculoskeletal Oncology Group will be excluded from this study.

Design outcomes

Primary

Measure	Time frame
Progressive-free survival	—

Secondary

Measure	Time frame
Survival Side effect (CTCAE)	—

Countries

Japan

Contacts

Public ContactHiroshi Kobayashi

The University of Tokyo Hospital Orthopaedic department

hkobayashi-tky@umin.ac.jp03-3815-5411

Outcome results